Skip to main content

Advertisement

Log in

Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

  • Original Articles: Various Topics
  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%–20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment IDUs infected with human immunodeficiency virus (HIV); HIV therapy was successfully provided to active heroin injectors using the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N=11); 77% (N=10) had nondetectable levels by 9 months. By 12 months, 54% (N=7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.

    Article  PubMed  Google Scholar 

  2. Update: trends in AIDS incidence—United States. MMWR Morb Mortal Wkly Rep. 1996;46:861–867.

  3. Whitman S, Murphy J, Cohen M, et al. Marked declines in HIV related mortality in Chicago in women, African Americans, Hispanics, young adults, and IDU’s, from 1995 through 1997. Arch Intern Med. 2000;160:365–369.

    Article  CAS  PubMed  Google Scholar 

  4. Bamberger JD, Unick J, Klein P, et al. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health. 2000;90:699–701.

    Article  CAS  PubMed  Google Scholar 

  5. Ferrando SJ, Wall TL, Batki SL, et al. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475–487.

    Article  CAS  PubMed  Google Scholar 

  6. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495–502.

    Article  CAS  PubMed  Google Scholar 

  7. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665–1670.

    Article  CAS  PubMed  Google Scholar 

  8. Wall TL, Sorensen JL, Batki SL, et al. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995;37:261–269.

    Article  CAS  PubMed  Google Scholar 

  9. Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care. 1995;7:439–447.

    Article  CAS  PubMed  Google Scholar 

  10. Williams A, Friedland GH. Adherence, compliance, and HAART. AIDS Clin Care. 1997;9(7):51–54, 58.

    CAS  PubMed  Google Scholar 

  11. Williams AB, Friedland GH. Substance abuse issues in women with HIV. In: Cotton DJ, Watts DH, eds. Medical Management of AIDS in Women. New York, NY: John Wiley and Sons; 1996;437–453.

    Google Scholar 

  12. Celantano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–546.

    Article  Google Scholar 

  13. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–549.

    Article  CAS  PubMed  Google Scholar 

  14. O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med. 1994;331:450–459.

    Article  CAS  PubMed  Google Scholar 

  15. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med. 1989;111:761–763.

    CAS  PubMed  Google Scholar 

  16. O’Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med. 1992;93:382–386.

    Article  CAS  PubMed  Google Scholar 

  17. Selwyn PA, Budner NS, Wasserman WC, et al. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108:492–500.

    CAS  PubMed  Google Scholar 

  18. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47–58.

    CAS  PubMed  Google Scholar 

  19. Dixon PS, Flanigan TP, DeBuono BA, et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med. 1993;95:629–635.

    Article  CAS  PubMed  Google Scholar 

  20. Mostashari F, Riley E, Selwyn PA, et al. Acceptance and adherence of antiretroviral therapy among HIV infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341–348.

    CAS  PubMed  Google Scholar 

  21. Heimer R, Kaplan EH, O’Keefe E, et al. Three years of needle exchange in New Haven: what have we learned? AIDS Public Policy J. 1994;9:59–74.

    Google Scholar 

  22. Barry M, Fleck E, Lentz S, Bell C, O’Connor P, Horwitz R. “Medicine on wheels”: an opportunity for outreach and housestaff education. Conn Med. 1994;58:535–539.

    CAS  PubMed  Google Scholar 

  23. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962–1969.

    Article  CAS  PubMed  Google Scholar 

  24. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:83–88.

    Article  CAS  PubMed  Google Scholar 

  25. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug user, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:461–466.

    CAS  PubMed  Google Scholar 

  26. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–259.

    CAS  PubMed  Google Scholar 

  27. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305–2315.

    Article  CAS  PubMed  Google Scholar 

  28. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS. 1999;13:2547–2554.

    Article  CAS  PubMed  Google Scholar 

  29. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the Euro SIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival J Acquir Immune Defic Syndr. 1999;22:369–378.

    CAS  PubMed  Google Scholar 

  30. Cheever LW, Wu AW. Medication adherence among HIV-infected patients: understanding the complex behavior of patients taking this complex therapy. Curr Infect Dis Rep. 1999;1:401–407.

    Article  PubMed  Google Scholar 

  31. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195–205.

    Article  CAS  PubMed  Google Scholar 

  32. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001;15:1115–1123.

    Article  CAS  PubMed  Google Scholar 

  33. Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA. 1998; 280:567–568.

    Article  CAS  PubMed  Google Scholar 

  34. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis. 1999;28:643–676.

    Article  CAS  PubMed  Google Scholar 

  35. Murray JS, Elashoff MR, Iacono-Connors LC, et al. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13:797–804.

    Article  CAS  PubMed  Google Scholar 

  36. The AVANTI Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet. 1999;353:2061–2064.

    Article  Google Scholar 

  37. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511–518.

    Article  CAS  PubMed  Google Scholar 

  38. Mitty JA, Stone VE, Sands M, et al. Directly Observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34:984–990.

    Article  PubMed  Google Scholar 

  39. Babudieri S, Aceti A, D’Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA. 2000;284:179–180.

    Article  CAS  PubMed  Google Scholar 

  40. Fischl M, Rodriguez, A, Scerpella R, et al. Impact of directly observed therapy on outcomes in HIV clinical trials. In: Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, CA. Abstract 71.

  41. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.

    CAS  PubMed  Google Scholar 

  42. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863–868.

    Article  CAS  PubMed  Google Scholar 

  43. Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000;14:1545–1552.

    Article  CAS  PubMed  Google Scholar 

  44. Marco A, Cayla JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Resp J. 1998;12:967–971.

    Article  CAS  Google Scholar 

  45. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468–480.

    Article  CAS  PubMed  Google Scholar 

  46. Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Reader. 2002;12:305–307, 312–316.

    PubMed  Google Scholar 

  47. Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observ therapy for treatment of human immunodeficiency virus. JAMA. 1999;282:1334.

    Article  CAS  PubMed  Google Scholar 

  48. Paterson DL, Swindells S, Mohr J, et al., Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    CAS  PubMed  Google Scholar 

  49. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–1423.

    Article  CAS  PubMed  Google Scholar 

  50. Daar ES, Cohen C, Remien R, et al. Improving adherence to antiretroviral therapy. AIDS Reader. 2003;13:81–90.

    PubMed  Google Scholar 

  51. McPherson-Baker S, Malow RM, Penedo F, et al. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care. 2000;12:399–404.

    Article  CAS  PubMed  Google Scholar 

  52. Malow RM, McPherson S, Klimas N, et al. Alcohol and drug abuse: adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998;49:1021–1024.

    CAS  PubMed  Google Scholar 

  53. Pollard RB. Can HIV infection be treated successfully with a once-daily regimen? AIDS Reader. 2002;12:489–500.

    PubMed  Google Scholar 

  54. Liebman J, Pat Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs. 2002;19(5):345–353.

    Article  PubMed  Google Scholar 

  55. Pollack HA, Khoshnood K, Blankenship KM et al. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002;17:341–348.

    Article  PubMed  Google Scholar 

  56. Leidy NK. Operationalizing Maslow’s theory: development and testing of the basic need satisfaction inventory. Issues Ment Health Nurs. 1994;15:277–295.

    Article  CAS  PubMed  Google Scholar 

  57. Craig RJ, Olson RE. Differences in psychological need hierarchy between program completers and dropouts from a drug abuse treatment program. Am J Drug Alcohol Abuse. 1988;14:89–96.

    Article  CAS  PubMed  Google Scholar 

  58. Acton GJ, Malathum P. Basic need status and health-promoting self-care behavior in adults. West J Nurs Res. 2000;22:796–811.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frederick L. Altice MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altice, F.L., Springer, S., Buitrago, M. et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 80, 416–427 (2003). https://doi.org/10.1093/jurban/jtg053

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/jtg053

Keywords

Navigation